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Cancer treatmentAbstract Aim of the study: Patients with cancer might have an increased risk for severe
outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with
a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer
and COVID-19.
Methods: This observational cohort study has been designed as a quality of care registry and is
executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collabora-
tion of oncology physicians in the Netherlands. A questionnaire has been developed to collect
pseudonymised patient data on patients’ characteristics, cancer diagnosis and treatment. All
patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible.
Results: Between March 27th and May 4th, 442 patients were registered. For this first analysis,
351 patients were included of whom 114 patients died. In multivariable analyses, age 65
years (p < 0.001), male gender (p Z 0.035), prior or other malignancy (p Z 0.045) and active
diagnosis of haematological malignancy (p Z 0.046) or lung cancer (p Z 0.003) were indepen-
dent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with
active malignancy, the risk for a fatal outcome was mainly determined by tumour type (hae-
matological malignancy or lung cancer) and age (65 years).
Conclusion: The findings in this registry indicate that patients with a haematological malig-
nancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the
ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute
respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccina-
tion, when available, should also be considered.
ª 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) outbreak, leading to coronavirus disease
2019 (COVID-19) [1,2], has major impact on healthcare
[3,4]. In particular, the consequences for oncological
care are extensive, as the effects of malignancy or cancer
treatments on the outcome of COVID-19 are yet un-
known [5e10]. In addition, hospital visits for anticancer
therapies may put patients at even more risk of getting
infected with SARS-CoV-2 [7,11]. Consequently, onco-
logical treatment was frequently adjusted during the
COVID-19 pandemic, even in regions with relatively low
COVID-19 incidence [12]. These treatment adjustments
were made according to COVID-19 guidelines of (inter)
national oncological societies, which were primarily
based on expert opinions [13e16].
Awaiting the development of vaccines against SARS-
CoV-2, new outbreaks are expected worldwide. A
nationwide registry was initiated by the Dutch Oncology
COVID-19 Consortium (DOCC). It aims to identify
characteristics of patients with cancer and/or their
treatments associated with a worse outcome of COVID-
19 to facilitate evidence-based decisions in oncological
care during this ongoing pandemic. In the Netherlands,
all patients have equal access to medical care and open
discussions with patients and their families about
treatment restrictions, i.e. do-not-intubate or do-not-
resuscitate orders, are daily practice.2. Methods
2.1. Study design
The registry is executed by DOCC, which is a nation-
wide consortium of oncology physicians (haematolo-
gists, medical oncologists, neuro-oncologists and
pulmonologists) in the Netherlands. This observational
cohort study was designed as a national quality of care
registry to support rapid clinical decision-making in
oncological practice. A questionnaire was developed to
collect pseudonymised patient data on four topics:
baseline patient characteristics, diagnosis and treatment
of cancer, characteristics of COVID-19 and treatment
and outcome of COVID-19 (appendix 2). Some patients
with COVID-19 were transferred to another hospital
because of capacity issues. Therefore, data of transfer of
patients between hospitals were requested to avoid du-
plicates. This registry was approved by the ethics com-
mittee and the Privacy Knowledge Office at Erasmus
Medical Centre. According to local hospital guidelines,
additional approval was obtained by local committees
when needed.
2.2. Inclusion criteria of DOCC registry
All patients with COVID-19 and a cancer diagnosis or
cancer treatment in the past 5 years were eligible for
inclusion in the DOCC registry. Besides, patients with a
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included if the diagnosis or treatment was expected to
have had an impact on COVID-19 outcome (e.g. bone
marrow transplantation, chest radiation therapy). The
diagnosis of COVID-19 was defined as a positive test for
SARS-CoV-2 using reverse transcription polymerase
chain reaction (RT-PCR) and/or radiological findings
on computed tomography (CT) and/or clinical symp-
toms of COVID-19. However, as a diagnosis of
COVID-19 based solely on clinical symptoms is insecure
and subject to bias, it was decided to restrict eligibility to
a PCR and/or CT-based COVID-19 diagnosis for this
analysis.2.3. Collection of data
The DOCC registry was initiated on March 27th, 2020,
and supported by the Dutch societies of medical on-
cologists, pulmonologists and neuro-oncologists
[17e19]. Dutch oncology physicians in all 69 hospital
organisations in the Netherlands were informed about
the registry by communications via different cancer so-
cieties. Physicians were encouraged to identify cancer
patients with COVID-19 and to collect pseudonymised
data using the questionnaire. Subsequently, the data
provided were centrally entered into an electronic clin-
ical record form (eCRF) using a secured digital database
(ALEA Clinical).2.4. Data processing
For the first analysis, an update on the course and
outcome of COVID-19 was requested for all patients
diagnosed with COVID-19  4 weeks before May 4th,
2020. Also, all clinical data in eCRFs were checked for
inconsistencies by experienced oncology physicians
(D.D., P.M., A.V.), and the queries generated were
sent to the participating hospitals. The returned
queries and updated data were processed in eCRFs.
Clinical data were both annotated and cleaned,
including the processing of transfer data to avoid
duplicates.2.5. Distribution of COVID-19 in the Netherlands
In the Netherlands, the COVID-19 pandemic is moni-
tored by The National Institute for Public Health and
the Environment [20]. All patients with a positive RT-
PCR test for SARS-CoV-2 are centrally registered.
The 12 geographic regions of the Netherlands were
classified according to the number of COVID-19 posi-
tive patients per 100,000 inhabitants. This allows eval-
uation of the national coverage of the DOCC registry
according to regional incidence of COVID-19.2.6. Statistical analysis
The characteristics of patients with resolved COVID-19
versus a fatal outcome of COVID-19 were analysed.
Descriptive statistics were used for baseline character-
istics. To analyse the risk for different age categories,
patients were categorised into three age groups; i.e. <65
years, 65e75 years and 75 years. Pearson’s chi-
square test was used to identify univariable risk factors
for a fatal outcome of COVID-19, and odds ratios were
presented with 95% confidence intervals. Variables with
p  0.10 in univariable analysis were included in
multivariable logistic regression analyses. This was done
with backward selection with a threshold of p < 0.05.
All statistical tests were performed two-sided. Data were
analysed using IBM SPSS statistics 25.
As patients with metastatic disease and/or active
cancer treatment could be more susceptible to a severe
course of COVID-19, a separate analysis was performed
for this subgroup of patients. Active malignancy was
defined as metastatic disease in patients with solid tu-
mours and/or recent cancer treatment (<90 days before
diagnosis of COVID-19). In patients with an active
malignancy, the impact of cancer treatment on COVID-
19 severity was also evaluated. For this group, treatment
was defined as any cancer treatment  30 days before
COVID-19 diagnosis. Finally, the impact of steroid use
was analysed as a possible risk factor for fatal outcome
of COVID-19. For this specific analysis, steroid use ( 
30 days before COVID-19 diagnosis) as supportive
medication for cytotoxic treatment (e.g. part of the
chemotherapeutic regime or anti-emetic medication)
versus steroid use not related to cancer treatment was
analysed.3. Results
3.1. COVID-19 in the Netherlands
At initiation of the registry, March 27th 2020, all Dutch
regions experienced an outbreak of COVID-19. At that
time, the Southern region of the Netherlands had the
highest incidence of COVID-19. Forty-five out of the 69
Dutch hospital organisations participated in the regis-
try. All hospitals that provided care for the majority of
patients with COVID-19 participated. The distribution
of COVID-19 and the location of participating hospitals
show nationwide coverage of this registry (Figure 1).
3.2. Characteristics of COVID-19 patients with cancer
Between March 27th and May 4th, 442 patients were
registered. Data from 409 cancer patients were complete
for the current analysis. In addition, the following pa-
tients were excluded form analyses: one duplicate case,
30 patients because of unconfirmed diagnosis of
Fig. 1. Prevalence of COVID-19 in the Netherlands. Patients with a positive test for SARS-CoV-2 at start of the DOCC registry March
28th, 2020 (a) and one day after the database lock on (b) May 5th, 2020. The black bullets indicate the hospitals that participated in the
registry (n Z 45).
Fig. 2. Patient selection. Flowchart of patient selection for the current analysis.
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Table 1
Patients’ characteristics.
Variable Resolved (n Z 237) Fatal (n Z 114) Total group (n Z 351)
Sexdn (%)
Male 112 (47.3) 75 (65.8) 187 (53.3)
Female 125 (52.7) 39 (34.2) 164 (46.7)
Age
Median age in years (interquartile range) 68 (59e76) 74 (68e80) 70 (61e77)
<65 yearsdn (%) 99 (41.8) 12 (10.5) 111 (31.6)
65 years < 75 yearsdn (%) 71 (30.0) 46 (40.4) 117 (33.3)
75 yearsdn (%) 67 (28.3) 56 (49.1) 123 (35.0)
Smokingdn (%)
All smokers 112 (47.3) 67 (58.5) 179 (51.0)
Current smoker 12 (5.1) 12 (10.5) 24 (6.8)
History of smoking 100 (42.2) 55 (48.2) 155 (44.2)
Comorbiditiesdn (%)
Cardiovascular disease 119 (50.2) 71 (62.3) 190 (54.1)
BMI  30 48 (20.3) 16 (14.0) 64 (18.2)
COPD 26 (11.0) 20 (17.5) 46 (13.1)
Diabetes mellitus 34 (14.3) 21 (18.4) 55 (15.7)
Autoimmune disease 13 (5.5) 9 (7.9) 22 (6.3)
Prior/other malignancy 31 (13.1) 32 (28.1) 63 (17.9)
Use of steroids at COVID-19 diagnosis 53 (22.4) 40 (35.1) 93 (26.5)
As part of cancer treatment (<1 week) 32 (13.5) 23 (20.2) 55 (15.7)
Use >1 week (not related to cancer treatment) 21 (8.9) 17 (14.9) 38 (10.8)
Cancer typedn (%)
Non-small-cell lung cancer 25 (10.5) 22 (19.3) 47 (13.4)
Breast cancer 40 (16.9) 7 (6.1) 47 (13.4)
Chronic lymphocytic leukaemia 22 (9.3) 9 (7.9) 31 (8.8)
Colorectal cancer 26 (11.0) 5 (4.4) 31 (8.8)
Prostate cancer 19 (8.0) 10 (8.8) 29 (8.3)
Multiple myeloma 14 (5.9) 14 (12.3) 28 (8.0)
Non-Hodgkin lymphoma 17 (7.2) 11 (9.6) 28 (8.0)
Urinary cell cancer 8 (3.4) 5 (4.4) 13 (3.7)
Myeloproliferative neoplasms 7 (3.0) 3 (2.6) 10 (2.8)
Myelodysplastic syndrome 4 (1.7) 5 (4.4) 9 (2.6)
Renal cell cancer 6 (2.5) 3 (2.6) 9 (2.6)
Melanoma 7 (3.0) 1 (0.9) 8 (2.3)
Endometrial cancer 6 (2.5) 1 (0.9) 7 (2.0)
Neuro-endocrine tumour 6 (2.5) 1 (0.9) 7 (2.0)
Oesophageal cancer 1 (0.4) 5 (4.4) 6 (1.7)
Chronic myeloid leukaemia 4 (1.7) 1 (0.9) 5 (1.4)
Ovarian cancer 4 (1.7) 0 (0) 4 (1.1)
Pancreatic cancer 4 (1.7) 0 (0) 4 (1.1)
Small-cell lung cancer 1 (0.4) 3 (2.6) 4 (1.1)
Other 14 (5.9) 8 (7.0) 24 (6.8)
Last oncological treatmentdn (%)
Surgery 25 (10.5) 17 (14.9) 42 (12.0)
Radiotherapy 43 (18.1) 24 (21.1) 67 (19.1)
Thoracic radiotherapy 27 (11.4) 16 (14.0) 43 (12.3)
Chemotherapy 104 (43.9) 49 (43.0) 153 (43.6)
Immunotherapy 41 (17.3) 16 (14.0) 57 (16.2)
Targeted therapy 39 (16.5) 17 (14.9) 56 (16.0)
Hormonal therapy 35 (14.8) 13 (11.4) 48 (13.7)
Disease stage solid tumoursdn (%)
Metastatic 81 (34.2) 31 (27.2) 112 (47.1)
Intention most recent cancer treatment givendn (%)
Curative 105 (44.3) 45 (39.5) 150 (42.7)
Non-curative 122 (51.5) 66 (57.9) 188 (53.6)
Unknown 10 (4.2) 3 (2.6) 13 (3.7)
Treatment restrictionsdn (%)
Do-not-intubate 82 (34.6) 95 (83.3) 177 (50.4)
BMI, body mass index; COPD, chronic obstructive pulmonary disease.
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Table 2
Univariable analysis of features of patients related to a fatal outcome of COVID-19.
Variable Odds ratio (95% CI) p value
Sex (male) 2.15 (1.35e3.41) 0.001
Age (years)
<65 years e e
65 years < 75 years 5.35 (2.64e10.81) <0.001
75 years 6.90 (3.44e13.84) <0.001
Smoking
All smokers e e
History of smoking 1.72 (1.03e2.88) 0.040
Active smoker 3.13 (1.28e7.64) 0.012
Comorbidities
Cardiovascular disease 1.64 (1.04e2.58) 0.034
BMI  30 0.64 (0.35e1.19) 0.158
COPD 1.73 (0.92e3.25) 0.087
Diabetes mellitus 1.35 (0.74e2.45) 0.325
Autoimmune disease 1.48 (0.61e3.56) 0.383
Prior/other malignancy 2.59 (1.49e4.52) 0.001
Use of steroids at COVID-19 diagnosis e e
As part of cancer treatment (<1 week) 1.94 (1.06e3.57) 0.033
Use >1 week (not related to cancer treatment) 2.18 (1.08e4.41) 0.029
Cancer type
Other e e
Haematological malignancy 2.15 (1.30e3.57) 0.003
Lung cancer 3.13 (1.64e5.95) 0.001
Last oncological treatment
Surgery 1.49 (0.77e2.88) 0.238
Radiotherapy 1.20 (0.69e2.10) 0.516
Thoracic radiotherapy 1.27 (0.65e2.47) 0.479
Chemotherapy 0.96 (0.61e1.51) 0.874
Immunotherapy 0.78 (0.42e1.46) 0.437
Targeted therapy 0.89 (0.48e1.65) 0.712
Hormonal therapy 0.74 (0.38e1.47) 0.390
Disease stage
Metastatic 0.87 (0.54e1.41) 0.575
Intention most recent cancer treatment given
Non-curative 1.30 (0.83e2.03) 0.259
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CI, confidence interval.
Table 3
Multivariable analysis of features of patients related to a fatal outcome
of COVID-19.
Variable Odds ratio (95% CI) p value
Sex (male) 1.84 (1.04e3.23) 0.035
Age (median age in years)
<65 years e e
65 years < 75 years 4.26 (1.89e9.58) <0.001
75 years 5.75 (2.56e12.92) <0.001
Comorbidities
Prior/other malignancy 2.02 (1.02e4.02) 0.045
Cancer type
Other e e
Haematological malignancy 1.89 (1.01e3.53) 0.046
Lung cancer 3.40 (1.51e7.64) 0.003
CI, confidence interval.
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19 with unknown outcome. For this first analysis, 351
patients were included (Figure 2).
Detailed baseline characteristics are presented in
Table 1. Overall, the median age was 70 years (inter-
quartile range [IQR] 61e77) and 187 (53.3%) patients
were male. The main cancer diagnoses were non-small
cell lung cancer (13.4%), breast cancer (13.4%) and
chronic lymphocytic leukaemia (8.8%). Metastatic dis-
ease was present in 112 (47.1%) out of 238 patients with
solid tumours. In more than half of all patients (53.6%),
the last cancer treatment was with non-curative intent.
Besides cancer diagnosis, most patients had one or more
relevant comorbidities, and 51% of the patients had a
history of smoking.
Before the COVID-19 diagnosis, cancer treatment
had been completed in 108 (30.8%) patients. In 101
(28.8%) patients, cancer treatment was not adjusted
during the COVID-19 outbreak. Adjustments before the
COVID-19 diagnosis included dose reduction (n Z 4,
1.1%), premature withdrawal of treatment (n Z 14,4.0%), administration of higher dose
(e.g. immunotherapy or radiotherapy) at longer interval
(n Z 16, 4.6%), cancellation of recent treatment cycle
(n Z 35, 10.0%) and/or temporarily interruption of
treatment (n Z 70, 19.9%).
Table 4
Univariable analysis for the subgroup of patients with active malignancy and COVID-19.
Variable Total group (n Z 227)
Frequency n (%) Odds ratio (95% CI) p value
Sex (male) 115 (50.7) 1.79 (1.01e3.17) 0.045
Age (median age in years)
<65 years 84 (37.0) e e
65 years < 75 years 77 (33.9) 4.72 (2.12e10.55) <0.001
75 years 66 (29.1) 6.55 (2.89e14.86) <0.001
Smoking
All smokers 115 (50.7) e e
History of smoking 99 (43.6) 1.20 (0.64e2.26) 0.579
Active smoker 16 (7.0) 2.63 (0.89e7.78) 0.082
Comorbidities
Cardiovascular disease 107 (47.1) 1.86 (1.06e3.29) 0.031
BMI  30 39 (17.2) 0.61 (0.27e1.36) 0.225
COPD 23 (10.1) 1.47 (0.61e3.58) 0.392
Diabetes mellitus 30 (13.2) 1.12 (0.49e2.52) 0.794
Autoimmune disease 10 (4.4) 1.49 (0.41e5.46) 0.543
Prior/other malignancy 38 (16.7) 1.77 (0.87e3.63) 0.115
Use of steroids at COVID-19 diagnosis 134 (59.0) e e
As part of cancer treatment (<1 week) 53 (23.3) 2.26 (1.16e4.40) 0.017
Use >1 week (not related to cancer treatment) 25 (11.0) 1.65 (0.67e4.09) 0.275
Cancer type
Other 127 (55.9) e e
Haematological malignancy 62 (27.3) 3.64 (1.89e7.04) <0.001
Lung cancer 38 (16.7) 2.53 (1.16e5.53) 0.020
Last oncological treatment
Surgery 15 (6.6) 1.51 (0.52e4.41) 0.451
Radiotherapy 49 (21.6) 0.85 (0.42e1.70) 0.645
Thoracic radiotherapy 31 (13.7) 0.88 (0.39e2.03) 0.772
Chemotherapy 117 (51.5) 0.88 (0.50e1.54) 0.648
Immunotherapy 46 (20.3) 0.84 (0.41e1.71) 0.621
Targeted therapy 49 (21.6) 1.22 (0.63e2.38) 0.560
Hormonal therapy 39 (17.2) 0.72 (0.33e1.57) 0.404
Disease stage for solid tumours
Metastatic 118 (52.0) 0.93 (0.53e1.63) 0.795
Intention most recent cancer treatment given
Non-curative 148 (65.2) 1.89 (1.01e3.53) 0.044
Treatment restrictions
Do-not-intubate 121 (53.3) e e
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CI, confidence interval.
Table 5
Multivariable analysis for the subgroup of patients with active ma-
lignancy and COVID-19.
Variable Odds ratio (95% CI) p value
Age (median age in years)
<65 years e e
65 years < 75 years 4.09 (1.70e9.89) 0.002
75 years 5.56 (2.21e14.02) <0.001
Cancer type
Other e e
Haematological malignancy 3.60 (1.72e7.53) 0.001
Lung cancer 3.01 (1.20e7.59) 0.019
CI, confidence interval.
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In total, 114 (32.3%) of the patients died from COVID-
19. Patients with a fatal outcome of COVID-19 had a
higher median age as compared with patients with non-
fatal outcome (74 [IQR 68e80] versus 68 [IQR 59e76]
years). Patients with age 65 years had an increased
risk of fatal outcome (p < 0.001). In univariable ana-
lyses (Table 2), male gender, smoking, cardiovascular
disease, chronic obstructive pulmonary disease, prior or
other malignancy, use of steroids at COVID-19 diag-
nosis, a current diagnosis of haematologic
malignancy and lung cancer were associated with fatal
outcome of COVID-19.
In multivariable analyses, age 65 years (p < 0.001),
male gender (p Z 0.035), prior or other malignancy
(p Z 0.045) and an active diagnosis of haematological
malignancy (p Z 0.046) or lung cancer (p Z 0.003)remained independent risk factors for a fatal outcome of
COVID-19 (Table 3).
Treatment restrictions with a do-not-intubate order
were reported in 117/351 (50.4%) patients and in 95/114
(83.3%) patients with fatal COVID-19 outcome.
Table 6
Overview of previously published registries.
Author Variable Dai [5] Liang [6]c Zhang [7] Lee [9]
Country China China China UK
Registry
(hospital and/
or general
practitioner)
Hospital
only
Hospital
only
Hospital
only
Hospital
only
Number of
patients with
cancer
105 18 out of
1590
COVID-19
patients had
cancer
26 800
Number of
hospitals
14 575 3 55
COVID-19
diagnosis
WHO interim
guidance
PCR PCR PCR
Study design Multicentre
prospective
cohort study
Prospective
cohort study
Retrospective
cohort study
Prospective
cohort study
Informed
consent
patients
No Not
reported
No Not
reported
Monitoring
of the data
Reviewed by
> 2 oncologists
Not
reported
Reviewed
by two
physicians
Not
reported
Population Cancer
diagnosis
from
Ever,
distributed
in several
cohortsb
Ever Ever Last
12 months
Lung cancer 22 (21%) 5/18 (28%) 7 (25%) 90 (11%)
Haematologic
cancer
9 (9%) 1/18 (6%)
(lymphoma)
0 169 (21%)
Other solid
tumours
Not
reported
12/18 (67%) 21 (75%) 494 (62%)
Treatment
status
Definition of
‘recent’
Within
40 days
Within
1 month
Within
14 days
Within
4 weeks
Recent
chemotherapy
17 4 (chemotherapy
or surgery)
3 281
Recent surgery 8 4 (chemotherapy
or surgery)
0 29
Recent
radiotherapy
13 0 1 76
Recent
immunotherapy
6 0 1 44
Recent hormonal
therapy
0 0 0 0
In follow-up Not
reported
12 12 Not
reported
Treatment
restrictions
Not
reported
Not
reported
Not
reported
Not
reported
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A subgroup analysis was performed in 227 patients with
active malignancy. The characteristics and results of the
univariable analysis are shown in Table 4. Patients with
a haematological malignancy or lung cancer had an
increased risk of a fatal outcome of COVID-19
compared with patients with other cancer types. In
addition, male patients, age 65 years, smoking, car-
diovascular disease and use of steroids as part of anti-
cancer treatment remained risk factors for fatal outcome
in univariable analysis. In this subgroup analysis,treatment in non-curative setting was also associated
with fatal outcome.
The above-mentioned characteristics were all
included in the multivariable analysis. The risk for a
fatal outcome was mainly determined by tumour type
and age, as older patients (65 years) and patients with
a haematological malignancy or lung cancer had a worse
outcome of COVID-19 (Table 5).
In total, 165 patients were on active treatment (i.e.
30 days between the last treatment and date of
COVID-19 diagnosis). In this group, there were no
differences in the risk of a fatal outcome of COVID-19
Data registered Baseline
characteristicsa
Yes Yes Yes Yes (including
covid-19 severity)
Laboratory
examination
Not
reported
Not
reported
Yes Not
reported
Abnormalities
at baseline
on X-ray or CT
Not
reported
Yes Yes Not
reported
Use of antibiotics Yes Not
reported
Yes Not
reported
Use of antiviral s Yes Not
reported
Yes Not
reported
Use of
hydroxychloroquine
Not
reported
Not
reported
Not
reported
Not
reported
Use of
glucocorticoids
Yes Not
reported
Yes Not
reported
Use of anti-IL6 Not
reported
Not
reported
Not
reported
Not
reported
Use of
anticoagulants
Not
reported
Not
reported
Not
reported
Not
reported
Admission to ICU Yes Yes Yes Yes
Invasive ventilation Yes Yes Yes Not
reported
Death Yes Yes Yes Yes
Other
DOCC, Dutch Oncology COVID-19 Consortium; ICU, intensive care unit; SARS-Cov-2, severe acute respiratory syndrome coronavirus 2; CT,
computed tomography.
a Age, smoking, comorbidity, cancer type, cancer treatment, COVID-19 symptoms.
b <3 months, 1e3 months, 3e6 months, 6e12 months, 1e3 years, >3 year.
c On behalf of the National Clinical Research Center for Respiratory Disease.
d Or longer if the cancer treatment is expected to have an impact on COVID-19 outcome, for example after bone marrow transplantation or
thoracic radiotherapy.
Garassino
(TERAVOLT)
[21]
Kuderer
(CCC1S)
[24]
Scarfo
[25]
Pinato
(OnCovid)
[26]
Lara
[27]
Robilotti
[28]
Joode
(DOCC)
8 countries USA, Canada
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Europe (UK,
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New York Memorial Sloan
Kettering Cancer
Center New York
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Hospital
only
Hospital
only
Hospital
only
Hospital
only
Hospital
only
Hospital
only
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study
Retrospective
cohort study
Multicentre
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study
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retrospective
observational
study
Multicentre
retrospective
observational
study
Retrospective
cohort study
Observational
cohort study
According to
local need
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reported
Yes Not
reported
Not
reported
Not
reported
No
Yes
(by REDCap)
Not
reported
Not
reported
Not
reported
Not
reported
Not reporter Data cleaned by
experienced
oncology physicians
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Not
reported
Not
reported
Ever Ever Ever Not
reported
Last 5 yeard
Only thoracic
malignancies
91 (10%);
thoracic cancer
0 119 (13%) 0 35 (8%) 51 (15%)
0 204 (22%) All haematologic
cancer
137 (15%) 0 102 (24%) 111 (32%)
Only thoracic
malignancies
667 (72%) 0 634 (71%) Only
gynaecological
cancer
286 (68%) 165 (47%)
Not
reported
Within
4 weeks
Within 12
months
Within
4 weeks
Not
reported
Within 30 days Within 30 days
68 160 Not
reported
206 35 191 117
0 2 Not
reported
0 11 31 15
0 12 Not
reported
33 9 Not
reported
49
54 38 Not
reported
56 8 31 46
0 0 Not
reported
92 9 Not
reported
39
52 (26%) Not
reported
73 403 52 Not
reported
108
Yes Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
With a do-not-
intubate order
Yes Yes Yes Yes Yes Yes Yes
Yes Not
reported
Not
reported
Yes Yes Yes Yes
Yes Not
reported
Not
reported
Not
reported
Not
reported
Yes Yes
Yes Not
reported
Not
reported
Yes Yes Yes Yes
Yes Not
reported
Yes Yes Yes Yes Yes
Yes Yes Yes Yes Yes Yes Yes
Yes Not
reported
Not
reported
Yes Yes Yes Yes
Yes Not
reported
Yes Yes Yes Yes Yes
Yes Not
reported
Yes Not
reported
Yes Not
reported
Not
reported
Yes Yes Not
reported
Yes Yes Yes Not
reported
Not
reported
Yes Not
reported
Yes Yes Yes Not
reported
Yes Yes Yes Yes Yes Yes Yes
Length of
hospital
stay
COVID-19
management
at home,
COVID-19
resolution
Occurrence
of complicated
SARS-Cov-2
infection
Adjustment of
oncological
treatment, treatment
restrictions regarding
mechanical ventilation
and admission to ICU
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setting (non-metastatic versus metastatic) and treat-
ment setting (curative versus non-curative) were not
associated with an increased risk of fatal outcome of
COVID-19.4. Discussion
The DOCC registry was initiated to identify clinical
characteristics of patients with cancer related to an
increased risk of fatal outcome of COVID-19. An active
diagnosis of haematological malignancy or lung cancer,
age (65 years), male gender and diagnosis of a prior or
K. de Joode et al. / European Journal of Cancer 141 (2020) 171e184 181other malignancy were independent risk factors for a
fatal outcome of COVID-19. In the subgroup of patients
with active malignancy, age (65 years) and a diagnosis
of a haematological malignancy or lung cancer remained
independent risk factors for increased mortality of
COVID-19.
Although chemotherapy has previously been identi-
fied as a risk factor for mortality of COVID-19 in cancer
patients [21], this could not be confirmed in our registry.
This is supported by data from a UK registry [9].
However, steroid use at the time of COVID-19 diagnosis
was associated with an increased risk of fatal outcome of
COVID-19 in univariable analysis. This result is of
particular interest, as a recent randomised clinical trial
showed that dexamethasone decreases mortality of
COVID-19 in patients requiring respiratory support
[22]. Steroids may contribute to an increased viral load
of SARS-CoV-2 by an increase in viral replication and a
delay of viral clearance [23]. Steroid co-medication is
usually prescribed as supportive medication for hae-
matological treatment and/or highly emetogenic
chemotherapy regimens. Therefore, systemic treatment
or disease itself cannot be excluded as confounding
factor.
Apart from the current DOCC registry, other inter-
national registries have been published to identify the
clinical characteristics of cancer patients with severe
COVID-19 [5e7,9,21,24e28]. As the design and data
collection of these registries are significantly different, a
comparison between results is challenging. Therefore,
for appropriate interpretation of data published by these
registries, attention should be paid to the different de-
signs and patient selections (Table 6).
At the beginning of the COVID-19 outbreak in the
Netherlands, both international and national oncolog-
ical guidelines were published [13e16]. In summary, the
national guidelines were rather reluctant to start or
continue oncological therapies. In addition, treating
physicians were encouraged to discuss treatment re-
strictions regarding intubation and ICU admission with
their patients. Owing to these conservative guidelines,
adjustments in oncological treatment were rather com-
mon [12] and probably even more frequent in vulnerable
patients. Therefore, the lack of effect of oncological
treatments on fatal outcomes of COVID-19 should be
interpreted cautiously in the current study, and the
impact of anticancer therapies on the course of COVID-
19 cannot be excluded.
Moreover, discussing treatment restrictions with pa-
tients in the outpatient clinic was already common
practice in the Netherlands prior to COVID-19, espe-
cially for patients with cancer in the non-curative
setting. In the DOCC registry, more than 50% of pa-
tients had a do-not-intubate order prior to infectionwith SARS-CoV-2. Among patients with fatal outcome
of COVID-19, more than 80% had a do-not-intubate
order. In addition, in the Netherlands, patients with
COVID-19 are almost solely admitted to the ICU when
mechanical ventilation is required, whereas most other
supportive treatments are given outside the ICU. As a
result, <20% of patients with fatal outcome of COVID-
19 was admitted to the ICU in the current study, despite
the lack of capacity issues of ICUs in the Netherlands.
Although discussing treatment restrictions is common
practice in the Netherlands and probably more common
as compared to other countries, the percentage of pa-
tients with a fatal outcome is comparable to other
countries [6,7,9,21,24]. Therefore, early discussion of
treatment restrictions with vulnerable patients is
preferred during this ongoing pandemic.
As the DOCC registry is only executed by oncology
physicians in hospitals, a limitation of this study is the
potential selection bias. As a result, particular groups of
patients may have been underreported. For instance,
patients who already had completed oncological treat-
ment, patients who were not admitted to the hospital or
patients who died in an out-hospital setting, may not
have been registered. Next, the Dutch testing policy for
SARS-CoV-2 was restrictive in the beginning of the
pandemic, which initially resulted in an underestimation
of the total number of patients with COVID-19.
Although a potential selection bias may have occurred,
this does not directly affect the results of this analysis, as
the potentially underreported patient groups mainly
included patients without active malignancy and/or
recent cancer treatment. In addition, the Dutch health-
care system provides equal access to medical care and
cancer treatment decisions are based on the same na-
tional guidelines. Therefore, the results of the current
study seem to be representative of a national cancer
patient population.
As the COVID-19 pandemic overwhelmed healthcare
systems worldwide, non-evidenceebased decisions had
to be made about the treatment of patients with non-
COVID-19 diseases such as cancer. Therefore, it is
essential to combine data from several international
registries and to ensure the collection of new and more
comprehensive data during this ongoing pandemic. In
particular, more data concerning cancer treatment and
supportive medication (e.g. steroids) should be collected.
In conclusion, the findings of the DOCC registry in
cancer patients confirm previous findings that older,
male patients with comorbidities have an increased risk
of a fatal outcome of COVID-19 [29]. Besides, the re-
sults of this registry indicate that patients with a hae-
matological malignancy or lung cancer have an
increased risk of a poorer outcome. During the ongoing
COVID-19 pandemic, these vulnerable patients should
K. de Joode et al. / European Journal of Cancer 141 (2020) 171e184182avoid exposure to SARS-CoV-2, whereas treatment
adjustments and prioritising vaccination, when avail-
able, should be considered as well.Conflict of interest statement
D.D. reports personal fees from speakers fee MSD,
personal fees from speakers fee Roche, personal fees
from speakers fee AstraZeneca, personal fees from
speakers fee BMS, personal fees from speakers fee
Novartis, personal fees from speakers fee Pfizer, outside
the submitted work; H.W. reports honoraria from
Astellas and Roche and travel expenses from Ipsen,
outside the submitted work; K.S. reports personal fees
and advisory role for Novartis, personal fees from
Roche, personal fees and advisory role for MSD, advi-
sory role BMS, advisory role Pierre Fabre, advisory role
Abbvie, outside the submitted work; L.H. reports other
from Boehringer Ingelheim, other from BMS, other
from Roche Genentech, other from BMS, grants from
Roche Genentech, grants from Boehringer Ingelheim,
other from AstraZeneca, personal fees from Quadia,
grants from Astra Zeneca, other from Eli Lilly, other
from Roche Genentech, other from Pfizer, other from
MSD, other from Takeda, non-financial support from
AstraZeneca, non-financial support from Novartis, non-
financial support from BMS, non-financial support from
MSD/Merck, non-financial support from GSK, non-
financial support from Takeda, non-financial support
from Blueprint Medicines, non-financial support from
Roche Genentech, other from Amgen, outside the sub-
mitted work; A.D. reports personal fees from Roche,
personal fees from Eli Lily, personal fees from Boeh-
ringer Ingelheim, personal fees from Pfizer, personal fees
from BMS, personal fees from Novartis, personal fees
from Takeda, personal fees from Pharmamar, non-
financial support from Abbvie, grants from BMS,
grants from Amgen, outside the submitted work; A.V.
reports advisory board of BMS, MSD, Merck, Pfizer,
Ipsen, Eisai, Pierre Fabre, Roche, Novartis, Sanofi,
outside the submitted work.
All remaining authors declare no competing interests.
Acknowledgements
The authors thank all the oncology physicians and
healthcare staff for their participation in the DOCC
registry during this COVID-19 pandemic. They would
like to thank S. Aammari and the Clinical Trial Center
Rotterdam for the design and implementation of the
study and S. Jeup for administrative support.
Appendix 1
Dutch Oncology COVID-19 Consortium (DOCC) con-
tributors list.C.J. van Loenhout1, C.H. van der Leest2, A. Becker-
Commissaris3, J.S.W. Borgers4, F. Terhegggen5,
B.E.E.M. van den Borne6, L.J.C. van Warmerdam7, L.
van Leeuwen8, F.S. van der Meer9, M.A. Tiemessen10,
D.M. van Diepen10, Y. Klaver11, A.P. Hamberg12, E.J.
Libourel13, L. Strobbe14, M. Cloos15, E.J. Geraedts16,
J.C. Drooger17, R. Heller18, J.W.B. de Groot19, J.A.
Stigt20, V.J.A.A. Nuij21, C.C.M. Pitz22, M. Slinger-
land23, F.J. Borm24, B.C.M. Haberkorn25, S.C. van ‘t
Westeinde26, M.J.B. Aarts27, J.W.G. van Putten28, M.
Youssef29, G.A. Cirkel30, G.J.M. Herder31, C.R. van
Rooijen32, E. Citgez33, N.P. Barlo34, B.M.J. Scholtes35,
R.H.T. Koornstra36, N.J.M. Claessens37, L.M. Faber38,
C.H. Rikers39, R.A.W. van de Wetering40, G.L. Veur-
ink41, B.W. Bouter42, I. Houtenbos43, M.P.L. Bard44,
K.H. Herbschleb45, E.A. Kastelijn46, P. Brocken47, G.
Douma48, M. Jalving49, T.J.N. Hiltermann50, O.C.J.
Schuurbiers-Siebers51, K.P.M. Suijkerbuijk52, A.S.R.
van Lindert53, A.J. van de Wouw54, V.E.M. van den
Boogaart55, S.D. Bakker56, E. Looysen57, A.L. Peerde-
man58, W.K. de Jong59, E.J.M. Siemerink60, A.J.
Staal61, B. Franken62, W.H. van Geffen63, G.P.
Bootsma.64
1Department of Pulmonology, Admiraal de Ruijter
Hospital, Goes, the Netherlands; 2Department of Pul-
monology, Amphia Hospital, Breda, the Netherlands;
3Department of Pulmonary Diseases, Cancer Center
Amsterdam, Amsterdam Medical Center, Vrije Uni-
versiteit Amsterdam, Amsterdam, The Netherlands;
4Department of Medical Oncology, The Netherlands
Cancer Institute (NKI), Amsterdam, The Netherlands;
5Department of Internal Medicine, Bravis Hospital,
Bergen op Zoom, The Netherlands; 6Department of
Pulmonary Diseases, Catharina Hospital, Eindhoven,
Netherlands; 7Department of Internal Medicine,
Catharina-Hospital, Eindhoven, The Netherlands;
8Department of Internal Medicine, Diakonessenhuis,
Utrecht, The Netherlands; 9Department of Pulmonol-
ogy, Diakonessenhuis, Utrecht, The Netherlands;
10Department of Pulmonology, Dijklander Hospital,
Purmerend, The Netherlands; 11Department of Internal
Medicine, Elisabeth-Tweesteden hospital, Tilburg, The
Netherlands; 12Department of Oncology, Franciscus
Gasthuis & Vlietland, Rotterdam, The Netherlands;
13Department of Internal Medicine, Franciscus Hospi-
tal, Rotterdam, the Netherlands.; 14Department of In-
ternal Medicine, Gelre Hospital, Zutphen, The
Netherlands; 15Department of Internal Medicine,
Groene Hart Hospital, Gouda, The Netherlands;
16Department of Pulmonology, Groene Hart Hospital,
Gouda, The Netherlands; 17Department of Medical
Oncology, Ikazia Hospital, Rotterdam, The
Netherlands; 18Department of Pulmonology, Ikazia
hospital, Rotterdam, The Netherlands; 19Department of
Medical Oncology, Isala Oncology Center, Zwolle, The
Netherlands; 20Department of Respiratory Medicine,
Isala Hospital, Zwolle, The Netherlands; 21Department
K. de Joode et al. / European Journal of Cancer 141 (2020) 171e184 183of Internal Medicine, Jeroen Bosch Hospital, ‘s-Herto-
genbosch, The Netherlands; 22Department of Pulmo-
nology, Laurentius Hospital, Roermond, The
Netherlands; 23Department of Medical Oncology, Lei-
den University Medical Center, Leiden, The
Netherlands; 24Department of Pulmonology, Leiden
University Medical Center, Leiden, The Netherlands;
25Department of Medical oncology, Maasstad Hospital,
Rotterdam, The Netherlands; 26Department of Pulmo-
nology, Maasstad Hospital, Rotterdam, The
Netherlands; 27Department of Medical Oncology,
Maastricht University Medical Centre, Maastricht, The
Netherlands; 28Department of Pulmonary Diseases,
Martini Hospital, Groningen, The Netherlands;
29Department of Respiratory Medicine, Máxima Medi-
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